Latest News and Press Releases

PALO ALTO, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...

First Phase 3 trial, COR1.1, on track for first quarter 2016 data availability Second Phase 3 trial, COR1.2, to enroll first patients in early 2016 with IND in first half 2016  NDA...

PALO ALTO, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...

PALO ALTO, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...

PALO ALTO, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...

PALO ALTO, Calif., May 19, 2015 (GLOBE NEWSWIRE) -- Carbylan® Therapeutics (Nasdaq:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination...

PALO ALTO, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, Inc. (Nasdaq:CBYL) (the "Company") today announced the closing of its initial public offering of 14,950,000 shares of its...

PALO ALTO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, Inc. (the "Company") today announced the pricing of its initial public offering of 13,000,000 shares of its common stock at...

PALO ALTO, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Carbylan Therapeutics, a pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced the...